Guidecraft Play Theater Recall Issued After Child Injured

About 1,800 play theaters by Guidecraft have been recalled because they may tip over unexpectedly, posing a risk of injury for young children playing with the theater. 

The Guidecraft Play Theater recall was announced by the U.S. Consumer Product Safety Commission (CPSC) on March 13, after the manufacturer, Guidecraft Inc., received at least two reports of incidents where the play theater tipped-over. One of the accidents resulted in a child suffering contusions and abrasions.

According to the CPSC, the play theaters pose an entrapment risk for children, because the tip-over incidents can occur unexpectedly during play.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The recall affects Guidecraft 4-in-1 Dramatic Play Theater Toys, with a model number of G51062. The model number is located on a sticker on the bottom of the center crossbar as well as in the assembly instructions. The 46-pound theaters have interchangeable panels with different themes.

The theaters were sold in various catalogs and online from Guidecraft.com as well as other internet retailers nationwide from July 2010 through April 2011 for about $180. They were made in China.

The CPSC recommends that consumers immediately take the recalled play theaters from children and contact Guidecraft in order to receive a full refund or a replacement product. Consumers with questions can call Guidecraft at (888) 824-1308 or visit the company’s website at www.guidecraft.com.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims.
As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis.
A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit.